Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC

NCT06841172 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

132

Enrollment

OTHER

Sponsor class

Conditions

OligoProgressive Metastatic Disease
Hepatocellular Carcinoma (HCC)
Radiotherapy
Systemic Therapy

Interventions

RADIATION: radiotherapy
DRUG: Systemic therapy (Continuation of current first-line systemic therapy)
DRUG: Systemic therapy (Early switch to second-line systemic therapy)

Sponsor

Shandong Cancer Hospital and Institute